Home > Boards > US Listed > Medical - Drugs > Merck & Co. Inc. (MRK)

Merck Receives Breakthrough Therapy Designation from FDA for

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
wagner Member Profile
 
Followed By 13
Posts 1,880
Boards Moderated 0
Alias Born 04/20/10
160x600 placeholder
Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellb... PR Newswire (US) - 1/18/2020 9:00:00 AM
Merck Completes Acquisition of ArQule Business Wire - 1/16/2020 8:34:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/15/2020 5:16:36 PM
AstraZeneca, Merck Get FDA Priority Review for Lynparza in Advanced Ovarian Cancer Dow Jones News - 1/13/2020 7:43:00 AM
 FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance ... Business Wire - 1/13/2020 6:55:00 AM
BriaCell Provides Update on Remarkable Responder GlobeNewswire Inc. - 1/13/2020 6:30:10 AM
Bristol-Myers Squibb, Macy's, Grubhub: Stocks That Defined the Week Dow Jones News - 1/10/2020 6:33:00 PM
BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade GlobeNewswire Inc. - 1/9/2020 6:30:10 AM
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder ... Business Wire - 1/8/2020 4:31:00 PM
Merck's Keytruda Study Shows Improvement for Patients Who Also Use Chemotherapy Dow Jones News - 1/6/2020 5:08:00 PM
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compar... Business Wire - 1/6/2020 4:05:00 PM
Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm PR Newswire (US) - 1/6/2020 11:07:00 AM
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex Business Wire - 1/6/2020 6:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2020 5:12:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2020 5:06:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2020 4:57:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2020 4:52:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2020 4:48:37 PM
Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5 Business Wire - 1/3/2020 6:45:00 AM
BriaCell Completes Share Consolidation GlobeNewswire Inc. - 1/2/2020 4:48:56 PM
Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire - 1/2/2020 6:45:00 AM
AstraZeneca, Merck Get FDA OK for Lynparza in Pancreatic Cancer Indication Dow Jones News - 12/30/2019 7:49:00 AM
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Canc... Business Wire - 12/30/2019 6:55:00 AM
BriaCell Therapeutics Corp. Announces Share Consolidation GlobeNewswire Inc. - 12/24/2019 6:30:10 AM
Merck Shares Up; FDA Approves Ebola Zaire Vaccine Ervebo Dow Jones News - 12/20/2019 12:21:00 PM
wagner   Wednesday, 01/30/19 10:32:21 AM
Re: None
Post # of 506 
Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccin...

Source: Business Wire
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age. V114 is also under development for the prevention of IPD in adults. Both indications are currently being studied in Phase 3 clinical trials.

The Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of drugs intended for serious or life-threatening conditions. To qualify for this designation, preliminary clinical evidence must demonstrate that the drug may provide substantial improvement over currently available therapy on at least one clinically significant endpoint. The benefits of this Breakthrough Therapy Designation include more intensive guidance from FDA on an efficient drug development program, access to a scientific liaison to help accelerate review time and eligibility for Accelerated Approval and Priority Review if relevant criteria are met.

The FDA’s decision was informed in part by immunogenicity data from two studies. Study 005 was a Phase 1/2, multicentre, randomized, double-blind study to evaluate the safety, tolerability and immunogenicity profiles of 4 different lots of a new formulation of V114 in healthy adults and infants. Study 008 was a proof of concept, Phase 2, pediatric trial to confirm the results from Study 005 in a larger population of infants. In both studies, V114 induced an immune response in infants for two disease-causing serotypes (22F and 33F) not contained in the currently available 13-valent pneumococcal conjugate vaccine, while demonstrating non-inferiority for the serotypes contained in both vaccines.

“We are pleased with the data on V114 compiled to date, and we look forward to working closely with the FDA on the subsequent development of this investigational vaccine,” said Dr. Nicholas Kartsonis, senior vice president and head of vaccine and infectious diseases clinical research at Merck Research Laboratories. “The goal of our program in pediatric patients remains focused on providing additional serotype coverage versus currently available vaccines, while at the same time maintaining a strong immune response across all serotypes in the vaccine.”

About Merck

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist